Jehn Melissa, Schmidt-Trucksäss Arno, Schuster Tibor, Weis Michael, Hanssen Henner, Halle Martin, Koehler Friedrich
Department of Prevention, Rehabilitation, and Sports Medicine, Technical University of Munich, Germany.
Am Heart J. 2009 Feb;157(2):292-8. doi: 10.1016/j.ahj.2008.10.006.
The purpose of this study was to use an accelerometer to measure daily walking performance in patients with chronic heart failure (CHF) to investigate if this parameter is a determinant of New York Heart Association class and indicative of maximal and functional exercise capacity.
Fifty patients with CHF were instructed to wear an accelerometer for 7 consecutive days while going about their daily business. Maximal and functional exercise capacity was assessed by cardiopulmonary (VO(2peak)) and 6-minute walk testing, respectively.
Patients in New York Heart Association I, II, and III reached an average total walking time (TWT) of 160.6 +/- 35.8 minutes, 133.9 +/- 59.0 minutes, and 76.1 +/- 22.5 minutes per day of which 19%, 19%, and 9% where spent in the fast walking mode (>83 m/minute), respectively. The TWT correlated strongly with VO(2peak) (r = 0.72; P <.001) and 6-minute walk testing distance (r = 0.68; P <.001). The TWT and time spent in fast walking mode were the strongest determinants in discriminating moderate CHF.
Daily walking performance is a clear determinant of maximal and functional exercise capacities in patients with CHF. Walking intensity in particular is an independent predictor in discriminating patients with advanced heart failure. Monitoring of daily walking performance might aid in detecting disease progression and improve clinical outcome.
本研究旨在使用加速度计测量慢性心力衰竭(CHF)患者的日常步行表现,以调查该参数是否为纽约心脏协会分级的决定因素,并指示最大运动能力和功能运动能力。
50例CHF患者被要求在日常活动时连续7天佩戴加速度计。分别通过心肺运动试验(VO₂峰值)和6分钟步行试验评估最大运动能力和功能运动能力。
纽约心脏协会I级、II级和III级的患者每天平均总步行时间(TWT)分别为160.6±35.8分钟、133.9±59.0分钟和76.1±22.5分钟,其中分别有19%、19%和9%的时间处于快走模式(>83米/分钟)。TWT与VO₂峰值(r = 0.72;P <.001)和6分钟步行试验距离(r = 0.68;P <.001)密切相关。TWT和处于快走模式的时间是区分中度CHF的最强决定因素。
日常步行表现是CHF患者最大运动能力和功能运动能力的明确决定因素。特别是步行强度是区分晚期心力衰竭患者的独立预测因素。监测日常步行表现可能有助于检测疾病进展并改善临床结局。